EncompaaS’ AI-Based Rebate Management Solution Can Save Pharma Firms up to 16,000 Hours in Manual Processing Annually

November 06, 2024 04:44 AM AEDT | By EIN Presswire
 EncompaaS’ AI-Based Rebate Management Solution Can Save Pharma Firms up to 16,000 Hours in Manual Processing Annually
Image source: EIN Presswire
VALENCIA, CA, UNITED STATES, November 5, 2024 /EINPresswire.com/ -- EncompaaS, a global leader in information management, today announced an enhanced version of its award-winning Rebate Management solution for pharmaceutical organizations, using AI to inspect complex rebate contracts and extract data with speed and accuracy. Customers can now visualize and analyze rebate management data in real-time, performing weeks of tedious, manual work in seconds.

EncompaaS’ Rebate Management solution empowers and equips pharmaceutical manufacturers to tackle the inherent difficulties in the sheer scale, scope and multiplicity of both rebate contracts and amendments within a single platform. Because rebate contracts can impact up to 25% of pharmaceutical revenue, it is critical that organizations understand their commercial position to maximize profitability and the bottom line.

“At EncompaaS, we understand the complexities involved in pharmaceutical rebate management, having worked closely with a global pharma manufacturer to successfully automate this critical business process touching core revenue streams,” said David Gould, Chief Customer Officer at EncompaaS.

“Using the EncompaaS platform, we have enabled this manufacturer to assess with accuracy the performance of vendors and the net effect of rebates on a drug’s revenue.”

Decision makers in a pharmaceutical organization, including Rebate Contract Managers, Sales and Product Managers, and Chief Legal Officers, can capitalize on the key advantages of EncompaaS’ solution:
• Visualize rebate sales data in seconds – Proactively monitor rebate sales targets and forecasts and identify previously undiscovered market gaps and opportunities.
• Accelerate time to information – Reduce manual effort and time spent extracting data and easily generate client reports based on accurate rebate data.
• Make informed decisions quickly – Quickly and easily assess risks related to contractual terms, monitor legal compliance and expedite decision making.
• Automate rebate contract analysis – Track the performance of drugs against contracted terms in real-time, maximizing efficiency and profitability.

EncompaaS’ Rebate Management solution has been successfully implemented, yielding real world results from one of the world’s largest pharmaceutical manufacturers. During the project, EncompaaS’ Rebate Management solution demonstrated the AI-powered analysis of over 10,000 contracts, yielding 140,000 data points extracted with 95% accuracy, resulting in 4,000 hours saved in manual processing per quarter. This led to tens of millions of dollars saved each year in their rebate program, with a 90% increase in identifying commercial or contractual risks in data.

“Using a combination of AI technologies, EncompaaS provides an automated way of tracking the performance of drugs against contracted terms quickly, while eliminating tedious manual processing,” added Jon Grundy, Senior Technical Consultant at EncompaaS.

“The machine learning technology is specifically designed for contract documents, and it’s already pre-trained on millions of other contracts, so it knows what a contract looks like and what terms and conditions to look for.”

EncompaaS’ award-winning transformational rebate management solution is available to pharmaceutical manufacturers now. To learn more about how their solution can revolutionize your rebate management processes and strategies, find EncompaaS’ Rebate Management Whitepaper here.

About EncompaaS
EncompaaS, a global leader in Information Management, empowers highly regulated organizations to rapidly mitigate compliance and privacy risks, while unlocking the full potential of their data. The platform uses next-generation AI technologies to find, enrich, and organize structured, unstructured and semi-structured data into a normalized data quality foundation. This enables automated governance at scale, ensuring information is de-risked, and prepares the highest quality data to fuel upstream processes for a variety of sectors, including pharmaceuticals, manufacturing, life sciences, financial services, insurance, utilities, education, and more. EncompaaS’ Rebate Management solution recently won the 2024 PharmaTech Award from the Global Tech Awards.

Headquartered in Sydney, with offices in the UK and USA, EncompaaS optimizes information on-premises and across multi-cloud environments and is trusted by Fortune 500 corporations, government departments and statutory authorities worldwide.

Luke Keding
HKA Marketing Communications
+1 315-575-4491
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.